Free Trial

BioNTech (BNTX) Competitors

BioNTech logo
$111.80 +1.75 (+1.59%)
As of 02:04 PM Eastern

BNTX vs. GSK, TAK, ARGX, ONC, TEVA, INSM, SMMT, ITCI, GMAB, and RDY

Should you be buying BioNTech stock or one of its competitors? The main competitors of BioNTech include GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

BioNTech vs. Its Competitors

BioNTech (NASDAQ:BNTX) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

BioNTech has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.

In the previous week, GSK had 15 more articles in the media than BioNTech. MarketBeat recorded 16 mentions for GSK and 1 mentions for BioNTech. GSK's average media sentiment score of 0.87 beat BioNTech's score of 0.47 indicating that GSK is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioNTech
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
GSK
9 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

GSK has a net margin of 9.89% compared to BioNTech's net margin of -27.37%. GSK's return on equity of 48.82% beat BioNTech's return on equity.

Company Net Margins Return on Equity Return on Assets
BioNTech-27.37% -3.94% -3.41%
GSK 9.89%48.82%11.15%

BioNTech presently has a consensus price target of $137.86, indicating a potential upside of 23.31%. GSK has a consensus price target of $37.38, indicating a potential downside of 2.39%. Given BioNTech's stronger consensus rating and higher probable upside, equities analysts plainly believe BioNTech is more favorable than GSK.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNTech
0 Sell rating(s)
4 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.83
GSK
1 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.11

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNTech$2.98B9.03-$719.92M-$3.40-32.88
GSK$40.10B1.96$3.29B$1.9419.74

Summary

GSK beats BioNTech on 10 of the 16 factors compared between the two stocks.

Get BioNTech News Delivered to You Automatically

Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BNTX vs. The Competition

MetricBioNTechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$26.88B$2.88B$5.46B$8.93B
Dividend YieldN/A2.44%5.24%4.04%
P/E Ratio-32.8820.9427.0720.17
Price / Sales9.03194.82381.5293.95
Price / CashN/A41.7026.2128.59
Price / Book1.287.518.015.59
Net Income-$719.92M-$55.04M$3.17B$248.41M
7 Day Performance3.99%5.25%3.53%6.17%
1 Month Performance3.05%2.30%2.73%7.83%
1 Year Performance38.90%5.33%34.10%21.03%

BioNTech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BNTX
BioNTech
1.5101 of 5 stars
$111.80
+1.6%
$137.86
+23.3%
+37.4%$26.88B$2.98B-32.886,772
GSK
GSK
2.3525 of 5 stars
$38.38
-0.5%
$37.38
-2.6%
-1.6%$78.58B$31.53B19.7890,100
TAK
Takeda Pharmaceutical
1.2918 of 5 stars
$15.46
+2.4%
N/A+14.1%$49.19B$30.09B70.2847,300
ARGX
argenex
4.3873 of 5 stars
$551.22
-1.6%
$729.93
+32.4%
+25.3%$33.66B$2.58B34.00650Analyst Upgrade
High Trading Volume
ONC
BeOne Medicines
2.9889 of 5 stars
$242.07
+0.4%
$320.67
+32.5%
N/A$26.53B$3.81B-65.079,000
TEVA
Teva Pharmaceutical Industries
4.1993 of 5 stars
$16.76
flat
$24.13
+43.9%
+2.7%$19.22B$16.54B-14.5736,800Positive News
Options Volume
INSM
Insmed
4.1249 of 5 stars
$100.64
+1.2%
$106.80
+6.1%
+38.5%$19.09B$363.71M-16.91740Positive News
Analyst Forecast
SMMT
Summit Therapeutics
2.4954 of 5 stars
$21.28
+3.3%
$35.09
+64.9%
+212.3%$15.80B$700K-62.59110
ITCI
Intra-Cellular Therapies
0.7441 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560News Coverage
GMAB
Genmab A/S
3.858 of 5 stars
$20.66
+0.8%
$37.60
+82.0%
-19.7%$13.25B$3.12B11.742,682Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7149 of 5 stars
$15.03
-0.3%
$16.95
+12.8%
-3.4%$12.55B$3.81B22.7727,811

Related Companies and Tools


This page (NASDAQ:BNTX) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners